Introduction

Coronary artery disease is the build-up of plaque, or narrowing or blockage of the coronary arteries, primarily due to atherosclerosis. Cholesterol or fatty acid gets deposited on the inner walls of the major blood vessels, which supply blood, oxygen, and nutrients to the heart, and damages them. The decreased blood flow leads to angina, shortness of breath, and other related symptoms, such as neck or jaw pain and sweating.

Statistically, coronary artery disease-based mortality has decreased in developed markets. It is still responsible, however, for one-third of all deaths in individuals above the age of 35, according to a 2016 publication in Annals of Translational Medicine. Presently, there are several biopharmaceutical companies expanding their pipeline to develop monoclonal antibodies, vaccines, and personalized medicine, to inhibit cholesterol production.

Report Coverage

This report by Mordor Intelligence provides extensive insights into the current scenario and growth prospects of the market studied. Detailed graphical representations of the pipeline landscape, based on various phases, and the status of clinical trials, across major regions of the world, are given, with data obtained from multiple sources. The report also comprises a list of key sponsors with pipeline products for the concerned market.

Coronary Artery Disease Clinical Trial Analysis by Phase and Status

• The clinical trial analysis for coronary artery disease indicates that there are around XX number of trials under various phases
• Phase X trials accounted for the majority share
• The trial data analysis suggests a number of ongoing trials, as well as ones that have been terminated

Coronary Artery Disease Analysis, by Geography

• By geography, the scope of the report covers the regional assessment for clinical trials, globally. It covers concise information regarding registered clinical trials in different countries, across several developed and emerging markets
• The factors such as High prevalence of heart diseases, along with the chronic nature of the disease is helping in the growth of the market. Technological advancements, with collaboration between science disciplines, such as biotechnology, and tissue engineering leading to novel therapeutic strategies are major factors for the growth of pipeline therapeutics for coronary artery diseases market

Key Sponsors in Coronary Artery Disease Clinical Trials

The report will cover analysis on trails and information on key sponsors, companies and researchers.

Research Methodology

Our data collection team builds scientific research models, based on data sourced from various internal databases, primary and secondary researches, and our in-house team of research experts. The pipeline assessment reports are generated based on information procured from various stakeholders, such as sponsors, clinical trial organizations, pharmaceutical companies, government bodies, trade agencies, industry journals, scientific literature databases, investor reports, press release statements, and several other sources. The data generated using secondary research and primary research is validated through discussions with industry KOL’s and C-suite executives. The data presented in the reports is continuously updated to incorporate the most relevant and authentic information to our clients.

Reasons to buy the report

This report will help you to understand

• The number of clinical trials that are being conducted worldwide
• The key products under development (Phase I, Phase II, and Phase III)
• The main areas of research under development (by product, mechanism of action, molecule, delivery, etc.)
• The average recruitment size in trials
• Key deals between institutions and industries
• Insights on regional- and country-level data
• Dormant and discontinued studies across the category
• Information on key sponsors and profiles
• Protocol and design comparisons, to generate the best solution for your product development strategy